Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975971 · ClinicalTrials.gov registry record
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
A clinical trial, sponsored by Nicole Fram M.D..
- Completed
- Registry status
- 25
- Enrollment target
NCT04975971: Completed study, sponsored by Nicole Fram M.D..
NCT04975971 is a clinical trial that has completed, run by Nicole Fram M.D.. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04975971 has completed, sponsored by Nicole Fram M.D..
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery
Primary Outcome
As measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worse pain possible
Interventions
- DRUG Dextenza 0.4Mg Ophthalmic Insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2021-05-19 |
What the finished NCT04975971 record still lists
NCT04975971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dextenza 0.4Mg Ophthalmic Insert is the first listed.
NCT04975971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04975971 about?
NCT04975971 is a clinical study titled "A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery". A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery
What is the current status of trial NCT04975971?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-03-09. Estimated completion is 2021-05-19.
What interventions are being tested in trial NCT04975971?
The interventions under investigation include: Dextenza 0.4Mg Ophthalmic Insert (DRUG).
Who is sponsoring clinical trial NCT04975971?
This trial is sponsored by Nicole Fram M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI